Absci (ABSI) director Menelas Pangalos awarded RSUs and stock options

Rhea-AI Filing Summary

Pangalos Menelas N reported acquisition or exercise transactions in this Form 4 filing.

Absci Corp director Menelas N. Pangalos reported equity awards tied to his role on the company’s scientific advisory board. He received stock options for 22,800 shares and a grant of 5,800 Restricted Stock Units (RSUs), both at no cash cost per share.

The RSUs are scheduled to vest and settle over one year beginning on January 1, 2026, in substantially equal monthly installments, conditioned on his continuous service. The stock options follow the same one-year, monthly vesting schedule starting on that date. Following the RSU grant, his directly held common stock position is 194,855 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Pangalos Menelas N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,800	$0.00	--
Grant/Award	Common Stock	5,800	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,800 shares (Direct); Common Stock — 194,855 shares (Direct)

Footnotes (1)

1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan in connection with service as a member of the scientific advisory board. The RSUs shall vest and be settled in full over a one year period beginning January 1, 2026, in substantially equal monthly installments, subject to the Reporting Person's continuous service through each vesting date. The shares subject to this option issued in connection with service as a member of the scientific advisory board shall vest and become exercisable over a one year period beginning January 1, 2026, in substantially equal monthly installments, subject to the Reporting Person's continuous service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pangalos Menelas N

(Last) (First) (Middle)

C/O ABSCI CORPORATION

18105 SE MILL PLAIN BOULEVARD

(Street)

VANCOUVER WA 98683

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Absci Corp [ ABSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		5,800(1)	A	$0	194,855	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.8	03/02/2026		A		22,800(2)		(2)	03/01/2036	Common Stock	22,800	$0	22,800	D

Explanation of Responses:

1. The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan in connection with service as a member of the scientific advisory board. The RSUs shall vest and be settled in full over a one year period beginning January 1, 2026, in substantially equal monthly installments, subject to the Reporting Person's continuous service through each vesting date.

2. The shares subject to this option issued in connection with service as a member of the scientific advisory board shall vest and become exercisable over a one year period beginning January 1, 2026, in substantially equal monthly installments, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Shelby Walker, attorney-in-fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Absci (ABSI) director Menelas N. Pangalos report?

He reported equity awards consisting of 22,800 stock options and 5,800 shares of common stock granted as Restricted Stock Units. Both awards relate to his service on Absci’s scientific advisory board and were recorded at a transaction price of $0.0000 per share.

How do the Absci (ABSI) RSU awards to Menelas N. Pangalos vest?

The 5,800 Restricted Stock Units vest and settle over one year starting January 1, 2026, in substantially equal monthly installments. Each monthly tranche requires Menelas N. Pangalos to remain in continuous service through the corresponding vesting date on Absci’s scientific advisory board.

What are the terms of the Absci (ABSI) stock options granted to Menelas N. Pangalos?

The option covers 22,800 shares of Absci common stock issued for scientific advisory board service. These options vest and become exercisable over one year beginning January 1, 2026, in substantially equal monthly installments, subject to his continuous service through each monthly vesting date.

What is Menelas N. Pangalos’s Absci (ABSI) common stock holding after these transactions?

After the March 2, 2026 grant of 5,800 RSU-based common shares, Menelas N. Pangalos directly holds 194,855 shares of Absci common stock. This figure reflects his ownership position following the reported equity award transaction as disclosed in the Form 4 filing.

Are the Absci (ABSI) equity awards to Menelas N. Pangalos tied to his ongoing service?

Yes. Both the 5,800 RSUs and the 22,800-share option vest over a one-year period starting January 1, 2026, in equal monthly installments. Each installment requires his continuous service on Absci’s scientific advisory board through the applicable vesting date.